REFERENCES
- Bailon P., Palleroni A., Schaffer C. A., Spence C. L., Fung W. J., Porter J. E., Ehrlich G. K., Pan W., Xu Z. X., Modi M. W., Farid A., Berthold W. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem 2001; 12: 195–202
- Delgado C., Francis G. E., Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst 1992; 9: 249–304
- Diwan M., Park T. G. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Rel 2001; 73: 233–244
- Diwan M., Park T. G. Stabilization of recombinant interferon-α by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm 2003; 252: 111–122
- Ellena J. F., Le M., Cafiso D. S., Solis R. M., Langston M., Sankaram M. B. Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv., 6: 97–106
- Eppstein D. A., Stewart W. E. 2nd Binding and capture of human interferon-alpha by reverse evaporation vesicles, multilamellar vesicles, and small unilamellar vesicles. J. Interferon Res 1981; 1: 495–504
- Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S. K., Salfi M., Jacobs S., Clement R. P. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 647–653
- Gregoriadis G. Overview of liposomes. J. Antimicrob. Chemother 1991; 28: 39–48
- Johansen P., Men Y., Audran R., Corradin G., Merkle H. P., Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharma. Res 1998; 15: 1103–1110
- Katre N. V., Asherman J., Schaefer H., Hora M. Multivesicular liposome (DepoFoam®) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J. Pharm. Sci 1998; 87: 1341–1346
- Katre N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol 1990; 144: 209–213
- Katre N. V. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Del. Rev 1993; 10: 91–114
- Kim S., Turker M. S., Chi E. Y., Sela S., Martin G. M. Preparation of multivesicular liposomes. Biochim. Biophys. Acta 1983; 728: 339–348
- Langston M. V., Ramprasad M. P., Kararli T. T., Galluppi G. R., Katre N. V. Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J. Control. Rel 2003; 89: 87–99
- Liang T. J., Rehermann B., Seeft L. B., Hoofnagle J. H. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann. Int. Med 2000; 132: 296–305
- Maghraby G. M., Williams A. C., Barry B. W. Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J. Pharm. Pharmacol 1999; 51: 1123–34
- Mantripragada S. A lipid based depot (Depofoam® Technology) for sustained release drug delivery. Prog. Lipid Res 2002; 41: 392–406
- New R. R. C. Liposomes: A practical approach, R.R.C. New. Informa UK Ltd, New York 1990; 33–104
- Bailon P., Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998; 1: 352–356
- Rubinstein S., Familletti P., Pestka S. Convenient assay for interferons. J. Virol 1981; 37: 755–758
- Vyas S. P., Khar R. K. Targeted and controlled drug delivery. Informa UK Ltd, New Delhi 2001
- Ye Q., Asherman J., Stevenson M., Brownson E., Katre N. V. DepoFoam® technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Rel 2000; 64: 155–166
- Zalipsky S., Harris J. M. Introduction to chemistry and biological applications of poly(ethylene) glycol. Poly(ethylene) glycol chemistry and biological applications, J. M. Harris, S. Zalipsky. Informa UK Ltd, Washington, DC 1997; 1–13